ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO424

Assessing the Quality of Life in Hemodialysis Patients with CKD-Associated Pruritus in Clinical Practice

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis


  • Kalantar-Zadeh, Kamyar, Harbor-UCLA Medical Center, Torrance, California, United States
  • Schaufler, Thilo, CSL Vifor, Glattbrugg, Switzerland
  • Latus, Joerg, Robert-Bosch-Krankenhaus GmbH, Stuttgart, Baden-Württemberg, Germany
  • Ruessmann, Despina, CSL Vifor, Glattbrugg, Switzerland
  • Morin, Isabelle, CSL Vifor, Glattbrugg, Switzerland
  • Menzaghi, Frederique, Cara Therapeutics Inc, Stamford, Connecticut, United States
  • Mccafferty, Kieran, Barts Health NHS Trust, London, London, United Kingdom

The detrimental impact of chronic kidney disease-associated pruritus (CKD-aP) on the quality of life (QoL) of hemodialysis (HD) patients has been well established in epidemiologic studies. However, diagnosis of CKD-aP and its consequences is not yet routine dialysis practice and no standard instrument is established.


KALM-1, KALM-2 and 3105 are phase-3 clinical studies evaluating safety and efficacy of difelikefalin in adult HD patients with moderate to severe CKD-aP. Itch intensity at baseline was assessed with the weekly average of the Worst Itching Intensity Numerical Rating Scale (WI-NRS, range 0 [no itch] to 10 [worst itch imaginable]) and defined as moderate (KALM-1: >4 to <7; KALM-2 and 3105 ≥5 to <7; N=448) or severe (≥7; N=625). We set out to compare the association between itch severity and QoL domains in this cohort. Itch-related QoL at baseline was assessed with Skindex-10 (Sk-10; range 0 to 60) and 5-D Itch (5-D; range 5 to 25) scales with higher values indicating worse impact on itch-related QoL.


Patients experiencing moderate / severe itch reported scores of 15.0 / 18.2 (5-D) and 29.3 / 39.7 (Sk-10), equivalent to 60.1% / 72.8% and 48.8% / 66.2% of the maximum for the corresponding scale respectively. Individual domains show a similar pattern. 5-D domains are relatively evenly balanced with Duration being an outlier at the lower end. Sk-10 was most influenced by the disease domain (Figure).


Either instrument can be useful in clinical practice: Sk-10 to complement WI-NRS with a differentiated measure of QoL and 5-D as a standalone option by combining itch intensity and impact on daily activities.


  • Commercial Support – CSL Vifor